期刊文献+

HIF-1α、Caspase-3及Survivin在胸腺瘤中的表达及意义 被引量:7

Expression and significance of HIF-1α,Caspase-3 and survivin protein in thymoma
原文传递
导出
摘要 目的研究缺氧诱导因子-lα(HIF-1α)、Caspase-3及Survivin在胸腺瘤的发生、发展中的作用。方法应用免疫组织化学SP法检测60例上皮性胸腺肿瘤和30例非肿瘤胸腺组织中HIF-1α、Caspase-3、Survivin蛋白的表达。结果HIF-1α蛋白在胸腺瘤组织中的阳性率为61.67%(37/60),显著高于非肿瘤胸腺组织阳性率3.33%(1/30)(P<0.01);在侵袭性胸腺瘤中的阳性率为84.62%(33/39),显著高于非侵袭性胸腺瘤阳性率19.05%(4/21)(P<0.01);在恶性胸腺瘤中的阳性率为73.91%(34/46),显著高于良性(或低度恶性)胸腺瘤中的阳性率21.43%(3/14)(P<0.01)。Caspase-3蛋白在胸腺瘤组织中的阳性率为28.33%(17/60),显著低于非肿瘤胸腺组织阳性率96.67%(29/30)(P<0.01);在侵袭性胸腺瘤中的阳性率为5.13%(2/39),显著低于非侵袭性胸腺瘤阳性率71.43%(15/21)(P<0.01);在恶性胸腺瘤中的阳性率为10.87%(5/46),显著低于良性(或低度恶性)胸腺瘤中的阳性率85.71%(12/14)(P<0.01)。Survivin蛋白在胸腺瘤组织中的阳性率为73.33%(44/60),显著高于非肿瘤胸腺组织阳性率6.67%(2/30)(P<0.01);在侵袭性胸腺瘤中的阳性率为92.31%(36/39),显著高于非侵袭性胸腺瘤阳性率38.10%(8/21)(P<0.01)。在恶性胸腺瘤中的阳性率为84.78%(39/46),显著高于良性(或低度恶性)胸腺瘤中的阳性率35.71%(5/14)(P<0.01)。结论HIF-1α、Caspase-3及Survivin与胸腺瘤的发生有关;与胸腺瘤的恶性程度及侵袭性有关。检测HIF-1α、Caspase-3与Survivin可作为判断胸腺瘤生物学行为的客观指标。 Objective To explore the effects of HIF-1α,caspase-3 and survivin protein in thymoma occurrence. Methods The expressions of HIF-1 α, caspase-3 and survivin protein were detected in 60 cases of thymoma and 30 cases of non-neoplastic thymus tissue by immunohistochemical SP assay. Results 1. HIF-1α. The immunohistochemical staining showed that HIF-1α obviously expressed in thymoma. The positive rate was 61.67% ( 37/60), significantly higher than non-neoplastic thymus tissue 3.33% ( 1/30 ) (P 〈 0. 01 ). The positive rate in invasive thymoma (Masaoka-stage Ⅰ) was 84. 62% (33/39), significantly higher than non-invasive thymoma( Masaoka-stage Ⅱ-Ⅲ )19. 05% (4/21) (P 〈 0. 01 ). The positive rate in malignant thymoma( WHO type B1 - B3 ) was 73. 91% (34/46), significantly higher than in benign thymoma ( WHO type A, AB ) 21.43% ( 3/14 ) ( P 〈 0. 01 ) ; 2. Caspase-3 : The positive rate of easpase-3 protein expressed in thymoma was 28. 33% (17/60), significantly lower than in non-neoplastic thymus tissue 96. 67% (29/30) (P 〈 0. 01 ). The positive rate in invasive thymoma was 5.13% (2/39), significantly lower than in non-invasive thymoma 71.43% ( 15/21 ) (P 〈 0. 01 ). The positive rate in malignant thymoma was 10. 87% (5/46), significantly lower than in benign thymoma 85. 71% ( 12/14 ) (P 〈 0. 01 ) ;3. Survivin: The positive rate of survivin protein was 73.33 % (44/60) expressed in thymoma, significantly higher than in non-neoplastic thymus tissue 6. 67% (2/30) (P 〈0. 01 ). The positive rate in invasive thymoma was 92. 31% (36/39), significantly higher than in non-invasive thymoma 38. 10% (8/21) (P 〈 0. 01 ). The positive rate in malignant thymoma was 84. 78% (39/46), significantly higher than in benign thymoma 35.71% (5/14) ( P 〈 0. 01 ). Conclusions HIF-1 α, easpase-3 and survivin were related to the genesis, malignant degree and invasive of thymoma. Detection of HIF-1α, caspase-3 and survivin could be used as the indicators to identify biological behavior of thymoma.
出处 《中华临床医师杂志(电子版)》 CAS 2009年第5期13-16,共4页 Chinese Journal of Clinicians(Electronic Edition)
关键词 胸腺瘤 缺氧诱导因子1 Α亚基 半胱氨酸天冬氨酸蛋白酶3 凋亡抑制蛋白质类 免疫组织化学 Thymoma Hypoxia-inducible factor 1, alpha subunit Caspase 3 Inhibitor of apoptosis proteins Immunohistochemistry
  • 相关文献

参考文献2

二级参考文献22

  • 1Shinohara, Gonzalez, Massion, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma [J]. Cancer, 2005, 103 (8):1685-1692.
  • 2Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting [J]. J Biol Chem, 1998, 273: 11177-11182.
  • 3Choi KS, Lee TH, Jung MH, et al. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells [J]. Cancer Gene Ther, 2003, 10 (2): 87-95.
  • 4Mesri M, Morales-Ruiz M, Ackermann E J, et al.Suppression of vascular endothelial growth factor-mediated endothelial cell protection by surviving targeting [J]. Am J Pathol, 2001, 158: 1757-1765.
  • 5Grossman D, Kim PJ, Seheehner JS, et al.Inhibition of melanoma tumor growth in vivo by survivin targeting [J].Proc Natl Acad Sci USA, 2001, 98: 635-640.
  • 6Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J]. Nat Med, 1997, 3: 917-921.
  • 7Fengzhi L, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle by survivin [J]. Nature, 1998,396: 580-588.
  • 8Caldas H, Honsey L E, Altura RA. Survivin 2 alphas a novel Survivin splice variant expressed in human malignancies[J].Mol Cancer, 2005, 4 (1): 11.
  • 9Mahotka C, Liebmann J, Wenzel M, et al. Differential subcellular localization of functionally divergent survivin splice variants [J]. Cell Death Differ, 2002, 9: 1334-1342.
  • 10Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin[J]. Biochem Biophys Res Commun, 2004, 314:902-907.

同被引文献57

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部